Adverse Events Associated With the Use of Sipuleucel-T Reported to the US Food and Drug Administration’s Adverse Event Reporting System, 2010-2017
Sign Up to like & getrecommendations! Published in 2019 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2019.9249
Abstract: Key Points Question What is the postmarketing safety profile of sipuleucel-T in the United States? Findings The US Food and Drug Administration’s Adverse Event Reporting System received 3216 reports for sipuleucel-T from 2010 through 2017.… read more here.
Keywords: reporting; administration adverse; adverse event; drug administration ... See more keywords
Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-18-0638
Abstract: Purpose: Sipuleucel-T is FDA approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC) based on the IMPACT trial showing a 4.1-month benefit in median overall survival (OS) for patients receiving sipuleucel-T versus control. Although… read more here.
Keywords: pa2024; ctl activity; cancer; pap ... See more keywords
Long-term Sculpting of the B-cell Repertoire following Cancer Immunotherapy in Patients Treated with Sipuleucel-T
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Immunology Research"
DOI: 10.1158/2326-6066.cir-20-0252
Abstract: Sipuleucel-T, an autologous cell–based immunotherapy, improves survival in castration-resistant prostate cancer patients, yet how this therapy induces antitumor B-cell immunity remains unclear. Sipuleucel-T induces long-term immune memory and lasting changes to the B-cell repertoire. Sipuleucel-T… read more here.
Keywords: cell repertoire; cancer; sipuleucel; long term ... See more keywords
Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-t alone in patients with metastatic castrate resistant prostate cancer.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.6_suppl.222
Abstract: 222Background: Sipuleucel-T (sip-T) is an autologous cellular vaccine indicated for patients (pts) with asymptomatic or minimally symptomatic metastatic castration resistant prostate cancer (mCRPC). Since radiation therapy (RT) can suppress the bone marrow function and immune… read more here.
Keywords: radiation therapy; prostate cancer; sip; resistant prostate ... See more keywords
Antigen (Ag) spread after sipuleucel-T and correlation with overall survival (OS): A real-world experience.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.e16504
Abstract: e16504 Background: Sipuleucel-T is an autologous cellular immunotherapy for asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. In IMPACT (NCT00065442), a phase 3 trial, sipuleucel-T-induced immune responses against target Ag prostatic acid phosphatase (PAP) or… read more here.
Keywords: sipuleucel; spread; responses secondary; real world ... See more keywords